- Overview
- Properties
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Generic Names: | Quinidine Gluconate; Quinidine Sulfate |
|---|---|
| IUPAC Name: | (S)-[(4S,5R,7R)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol |
| Trade Names: | Apo-Quinidine; Biquin Durules; Cardioquin; Chinidin; Cin-Quin; Coccinine; Conchinin; Conchinine; Conquinine; Duraquin; Kinidin; Novoquinidin; Pitayin; Pitayine; Quin-Release; Quinact; Quinaglute; Quinaglute Dura-Tabs; Quinalan; Quinate; Quinatime; Quindine; Quinicardine; Quinidex; Quinidex Extentabs; Quinora |
| PharmGKB Accession Id: | PA451209 |
Description
An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. [PubChem]
Indication
For the treatment of ventricular pre-excitation and cardiac dysrhythmias
ATC Therapeutic Category
- C01BA:Antiarrhythmics, class Ia
Pharmacology and Interactions
Mechanism Of Action
Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.
Pharmacology
Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.
Food Interactions
Preferably take on an ampty stomach.
Absorption, Distribution, Metabolism, Elimination & Toxicity
Protein Binding
80-88%
Half Life
6-8 hours
Chemical Properties
Chemical Formula:
C20H24N2O2
SMILES Code:
COc1ccc2c(c1)c(ccn2)[C@@H]([C@@H]3CC4CCN3C[C@H]4C=C)O
(Format: OpenEye Isomeric)
Molecular Weight ( average / monoisotopic )
324.4168 / 324.1838
Curated Information
The following genes are in curated knowledge about this drug.
Non-Curated Information
A list of non-curated publications that mention this drug along with other genes is available.
Metabolizing Enzymes
Drug Targets
PharmGKB Curated Pathways
Curated Information
The following drugs are in curated knowledge about this drug.
| Drug | Relationship | Evidence | |
|---|---|---|---|
|
|
donepezil |
|
Publications |
|
|
galantamine |
|
Publications |
|
|
hydrocodone |
|
Publications |
|
|
warfarin |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| acenocoumarol | Quinine/quinidine increases the anticoagulant effect |
| amiloride | Amiloride decreases the antiarrhythmic effect of quinidine |
| amiodarone | Amiodarone increases the effect of quinidine |
| amitriptyline | Quinidine increases the effect of the tricyclic agent |
| amobarbital | The anticonvulsant decreases the effect of quinidine |
| anisindione | Quinine/quinidine increases the anticoagulant effect |
| aprobarbital | The anticonvulsant decreases the effect of quinidine |
| aripiprazole | Quinidine increases the effect and toxicity of aripiprazole |
| atazanavir | Increased risk of cardiotoxicity/arrhythmias |
| atomoxetine | The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine |
| atracurium | The quinine derivative increases the effect of the muscle relaxant |
| butabarbital | The anticonvulsant decreases the effect of quinidine |
| butalbital | The anticonvulsant decreases the effect of quinidine |
| butethal | The anticonvulsant decreases the effect of quinidine |
| cimetidine | Cimetidine increases the effect of quinidine |
| cisapride | Increased risk of cardiotoxicity and arrhythmias |
| clarithromycin | Increased risk of cardiotoxicity and arrhythmias |
| clomipramine | Quinidine increases the effect of the tricyclic agent |
| codeine | Quinidine decreases the analgesic effect of codeine |
| desipramine | Quinidine increases the effect of the tricyclic agent |
| dextromethorphan | Quinidine increases the toxicity of dextromethorphan |
| dicumarol | Quinine/quinidine increases the anticoagulant effect |
| digitoxin | Quinine/quinidine increases the effect of digoxin |
| digoxin | Quinine/quinidine increases the effect of digoxin |
| dihydroquinidine barbiturate | The anticonvulsant decreases the effect of quinidine |
| diltiazem | Diltiazem increases the effect and toxicity of quinidine |
| donepezil | Possible antagonism of action |
| doxepin | Quinidine increases the effect of the tricyclic agent |
| erythromycin | Increased risk of cardiotoxicity and arrhythmias |
| fosphenytoin | The anticonvulsant decreases the effect of quinidine |
| galantamine | Possible antagonism of action |
| gallamine triethiodide | The quinine derivative increases the effect of the muscle relaxant |
| gatifloxacin | Increased risk of cardiotoxicity and arrhythmias |
| grepafloxacin | Increased risk of cardiotoxicity and arrhythmias |
| heptabarbital | The anticonvulsant decreases the effect of quinidine |
| hexobarbital | The anticonvulsant decreases the effect of quinidine |
| imipramine | Quinidine increases the effect of the tricyclic agent |
| itraconazole | The imidazole increases the effect and toxicity of quinidine |
| ketoconazole | The imidazole increases the effect and toxicity of quinidine |
| levofloxacin | Increased risk of cardiotoxicity and arrhythmias |
| magnesium | The antacid increases the effect of quinidine |
| mesoridazine | Increased risk of cardiotoxicity and arrhythmias |
| methohexital | The anticonvulsant decreases the effect of quinidine |
| methylphenobarbital | The anticonvulsant decreases the effect of quinidine |
| metocurine | The quinine derivative increases the effect of the muscle relaxant |
| moxifloxacin | Increased risk of cardiotoxicity and arrhythmias |
| nelfinavir | Nelfinavir increases the effect and toxicity of quinidine |
| nifedipine | Decreased quinidine effect, increased nifedipine effect |
| nortriptyline | Quinidine increases the effect of the tricyclic agent |
| ofloxacin | Increased risk of cardiotoxicity and arrhythmias |
| pancuronium | The quinine derivative increases the effect of the muscle relaxant |
| pentobarbital | The anticonvulsant decreases the effect of quinidine |
| phenobarbital | The anticonvulsant decreases the effect of quinidine |
| phenytoin | The anticonvulsant decreases the effect of quinidine |
| posaconazole | Contraindicated co-administration |
| primidone | The anticonvulsant decreases the effect of quinidine |
| procainamide | Quinidine increases the effect of procainamide |
| propafenone | Quinidine increases the effect of propafenone |
| protriptyline | Quinidine increases the effect of the tricyclic agent |
| quinidine barbiturate | The anticonvulsant decreases the effect of quinidine |
| quinupristin | This combination presents an increased risk of toxicity |
| ranolazine | Possible additive effect on QT prolongation |
| rifampin | Rifampin decreases the effect of quinidine |
| ritonavir | Ritonavir increases the effect and toxicity of quinidine |
| rivastigmine | Possible antagonism of action |
| salicylate-magnesium | The antacid increases the effect of quinidine |
| secobarbital | The anticonvulsant decreases the effect of quinidine |
| sodium bicarbonate | The antacid increases the effect of quinidine |
| sparfloxacin | Increased risk of cardiotoxicity and arrhythmias |
| succinylcholine | The quinine derivative increases the effect of the muscle relaxant |
| talbutal | The anticonvulsant decreases the effect of quinidine |
| telithromycin | Increased risk of cardiotoxicity and arrhythmias |
| terfenadine | Increased risk of cardiotoxicity and arrhythmias |
| thioridazine | Increased risk of cardiotoxicity and arrhythmias |
| trimipramine | Quinidine increases the effect of the tricyclic agent |
| vecuronium | The quinine derivative increases the effect of the muscle relaxant |
| verapamil | Verapamil increases the effect of quinidine |
| voriconazole | Increased risk of cardiotoxicity and arrhythmias |
| warfarin | Quinine/quinidine increases the anticoagulant effect |
| ziprasidone | Increased risk of cardiotoxicity and arrhythmias |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- Drug-Induced Long QT Intervals




- PD
Submitted by Dan Roden, MD involving ADRB1, ADRB2, KCNE1, KCNE2, KCNH2, KCNQ1, SCN5A, almokalant, amiodarone, amitriptyline, bretylium, bupivacaine, cisapride, disopyramide, dofetilide, encainide, fluconazole, haloperidol, hydroquinidine, isoflurane, itraconazole, ketoconazole, lithium, loratadine, metoclopramide, nortriptyline, procainamide, quinidine, sematilide, sotalol, sulfamethoxazole, thioridazine, trimethoprim, , Long QT Syndrome, Proarrhythmia and Torsades de Pointes - SLC22A2 Functional Protein Variants




- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , cimetidine, metformin, MPP+, phenformin, procainamide and quinidine - Xenopus expression of variant SLC22A2 proteins




- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , metformin, MPP+, phenformin, procainamide and quinidine
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
